## GRAL: GRAIL, Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 4.2% in lower entry zone (4.0-10.0%), top quartile (83rd pct) cross-sectional ranking. Short-term MRS_5 (7.8%) confirms momentum alignment. Strong momentum (+11.2% 5-day acceleration). Outperforming sector by 3.7%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($84.01)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 39.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 4 |

**Top Holders:**
- Blackrock Inc.: 6.3% (+0.7%)
- Primecap Management : 5.2% (-1.6%)
- CRCM LP: 4.7% (-49.5%)
- Vanguard Group Inc: 4.7% (-4.5%)
- Baker Bros. Advisors: 4.2% (0.0%)

### Key Risks

1. High beta (3.51) amplifies market volatility - any risk-off move could trigger sharp selloff.
2. Elevated short interest (13.8%): bears positioning against stock.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- Momentum building: MRS_20 improving +11.2% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Balance sheet: strong liquidity (7.6x), low leverage (D/E 0.16). Institutional flow bullish (4 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $3.7B |
| Beta | 1.00 |
| 52W Range | $16.56 - $115.76 |
| Short Interest | 13.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | N/A |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 strengthening from -6.9% to 4.2% (+11.2% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 83rd percentile. MRS_5 at 7.8% confirms short-term momentum alignment. AM_20 at 4.4% shows strong absolute momentum above own 20MA. Outperforming sector by 3.7pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 56. OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 4.24% (CS: 83) | Strong |
| RSI_14 | 55.9 | Neutral |
| MACD Histogram | -0.34 | Bearish |
| vs SMA20 | 1.044x | Above |
| vs SMA50 | 1.052x | Above |
| vs SMA200 | 1.801x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $95.75
- **Stop Loss:** $84.01 (12.3% risk)
- **Target:** $113.36 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 73
- **Position Value:** $6,989.75
- **Portfolio %:** 6.99%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-19 (Est: $-2.90)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-3.27 | $-2.46 | +24.7% |
| 2025Q2 | $-3.56 | $-3.18 | +10.8% |
| 2025Q1 | $-3.80 | $-3.10 | +18.5% |
| 2024Q4 | $-4.97 | $-2.89 | +41.9% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_20*